2wkl

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
m (Protected "2wkl" [edit=sysop:move=sysop])
Current revision (01:29, 21 November 2024) (edit) (undo)
 
(12 intermediate revisions not shown.)
Line 1: Line 1:
-
[[Image:2wkl.png|left|200px]]
 
-
<!--
+
==Velaglucerase alfa==
-
The line below this paragraph, containing "STRUCTURE_2wkl", creates the "Structure Box" on the page.
+
<StructureSection load='2wkl' size='340' side='right'caption='[[2wkl]], [[Resolution|resolution]] 2.70&Aring;' scene=''>
-
You may change the PDB parameter (which sets the PDB file loaded into the applet)
+
== Structural highlights ==
-
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+
<table><tr><td colspan='2'>[[2wkl]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2WKL OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2WKL FirstGlance]. <br>
-
or leave the SCENE parameter empty for the default display.
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.7&#8491;</td></tr>
-
-->
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-
{{STRUCTURE_2wkl| PDB=2wkl | SCENE= }}
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2wkl FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2wkl OCA], [https://pdbe.org/2wkl PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2wkl RCSB], [https://www.ebi.ac.uk/pdbsum/2wkl PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2wkl ProSAT]</span></td></tr>
 +
</table>
 +
== Disease ==
 +
[https://www.uniprot.org/uniprot/GBA1_HUMAN GBA1_HUMAN] Gaucher disease type 3;Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome;Gaucher disease type 1;Hereditary late-onset Parkinson disease;Gaucher disease type 2;Fetal Gaucher disease;NON RARE IN EUROPE: Dementia with Lewy body;NON RARE IN EUROPE: Parkinson disease. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry. Perinatal lethal Gaucher disease is associated with non-immune hydrops fetalis, a generalized edema of the fetus with fluid accumulation in the body cavities due to non-immune causes. Non-immune hydrops fetalis is not a diagnosis in itself but a symptom, a feature of many genetic disorders, and the end-stage of a wide variety of disorders.<ref>PMID:10352942</ref> Disease susceptibility may be associated with variants affecting the gene represented in this entry.
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/GBA1_HUMAN GBA1_HUMAN] Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose (PubMed:15916907, PubMed:24211208, PubMed:32144204, PubMed:9201993). Plays a central role in the degradation of complex lipids and the turnover of cellular membranes (PubMed:27378698). Through the production of ceramides, participates in the PKC-activated salvage pathway of ceramide formation (PubMed:19279011). Catalyzes the glucosylation of cholesterol, through a transglucosylation reaction where glucose is transferred from GlcCer to cholesterol (PubMed:24211208, PubMed:26724485, PubMed:32144204). GlcCer containing mono-unsaturated fatty acids (such as beta-D-glucosyl-N-(9Z-octadecenoyl)-sphing-4-enine) are preferred as glucose donors for cholesterol glucosylation when compared with GlcCer containing same chain length of saturated fatty acids (such as beta-D-glucosyl-N-octadecanoyl-sphing-4-enine) (PubMed:24211208). Under specific conditions, may alternatively catalyze the reverse reaction, transferring glucose from cholesteryl 3-beta-D-glucoside to ceramide (Probable) (PubMed:26724485). Can also hydrolyze cholesteryl 3-beta-D-glucoside producing glucose and cholesterol (PubMed:24211208, PubMed:26724485). Catalyzes the hydrolysis of galactosylceramides/GalCers (such as beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine), as well as the transfer of galactose between GalCers and cholesterol in vitro, but with lower activity than with GlcCers (PubMed:32144204). Contrary to GlcCer and GalCer, xylosylceramide/XylCer (such as beta-D-xyosyl-(1<->1')-N-acylsphing-4-enine) is not a good substrate for hydrolysis, however it is a good xylose donor for transxylosylation activity to form cholesteryl 3-beta-D-xyloside (PubMed:33361282).<ref>PMID:15916907</ref> <ref>PMID:19279011</ref> <ref>PMID:24211208</ref> <ref>PMID:26724485</ref> <ref>PMID:27378698</ref> <ref>PMID:32144204</ref> <ref>PMID:33361282</ref> <ref>PMID:9201993</ref> <ref>PMID:32144204</ref>
 +
== Evolutionary Conservation ==
 +
[[Image:Consurf_key_small.gif|200px|right]]
 +
Check<jmol>
 +
<jmolCheckbox>
 +
<scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/wk/2wkl_consurf.spt"</scriptWhenChecked>
 +
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked>
 +
<text>to colour the structure by Evolutionary Conservation</text>
 +
</jmolCheckbox>
 +
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=2wkl ConSurf].
 +
<div style="clear:both"></div>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Gaucher disease, the most common lysosomal storage disease, can be treated with enzyme replacement therapy (ERT), in which defective acid-beta-glucosidase (GlcCerase) is supplemented by a recombinant, active enzyme. The X-ray structures of recombinant GlcCerase produced in Chinese hamster ovary cells (imiglucerase, Cerezyme) and in transgenic carrot cells (prGCD) have been previously solved. We now describe the structure and characteristics of a novel form of GlcCerase under investigation for the treatment of Gaucher disease, Gene-Activated human GlcCerase (velaglucerase alfa). In contrast to imiglucerase and prGCD, velaglucerase alfa contains the native human enzyme sequence. All three GlcCerases consist of three domains, with the active site located in domain III. The distances between the carboxylic oxygens of the catalytic residues, E340 and E235, are consistent with distances proposed for acid-base hydrolysis. Kinetic parameters (K(m) and V(max)) of velaglucerase alfa and imiglucerase, as well as their specific activities, are similar. However, analysis of glycosylation patterns shows that velaglucerase alfa displays distinctly different structures from imiglucerase and prGCD. The predominant glycan on velaglucerase alfa is a high-mannose type, with nine mannose units, while imiglucerase contains a chitobiose tri-mannosyl core glycan with fucosylation. These differences in glycosylation affect cellular internalization; the rate of velaglucerase alfa internalization into human macrophages is at least 2-fold greater than that of imiglucerase.
-
===VELAGLUCERASE ALFA===
+
Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages.,Brumshtein B, Salinas P, Peterson B, Chan V, Silman I, Sussman JL, Savickas PJ, Robinson GS, Futerman AH Glycobiology. 2010 Jan;20(1):24-32. Epub 2009 Sep 9. PMID:19741058<ref>PMID:19741058</ref>
-
 
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
<!--
+
</div>
-
The line below this paragraph, {{ABSTRACT_PUBMED_19741058}}, adds the Publication Abstract to the page
+
<div class="pdbe-citations 2wkl" style="background-color:#fffaf0;"></div>
-
(as it appears on PubMed at http://www.pubmed.gov), where 19741058 is the PubMed ID number.
+
-
-->
+
-
{{ABSTRACT_PUBMED_19741058}}
+
-
 
+
-
==About this Structure==
+
-
[[2wkl]] is a 2 chain structure of [[Acid-beta-glucosidase]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2WKL OCA].
+
==See Also==
==See Also==
-
*[[Acid-beta-glucosidase|Acid-beta-glucosidase]]
+
*[[Acid-beta-glucosidase 3D structures|Acid-beta-glucosidase 3D structures]]
-
*[[Partially deglycosylated acid-beta-glucosidase|Partially deglycosylated acid-beta-glucosidase]]
+
*[[Beta-glucosidase|Beta-glucosidase]]
-
*[[Treatment of Gaucher disease|Treatment of Gaucher disease]]
+
== References ==
-
*[[Velaglucerase alfa|Velaglucerase alfa]]
+
<references/>
-
 
+
__TOC__
-
==Reference==
+
</StructureSection>
-
<ref group="xtra">PMID:019741058</ref><references group="xtra"/>
+
-
[[Category: Glucosylceramidase]]
+
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
-
[[Category: Brumshtein, B.]]
+
[[Category: Large Structures]]
-
[[Category: Chan, V.]]
+
[[Category: Brumshtein B]]
-
[[Category: Futerman, A H.]]
+
[[Category: Chan V]]
-
[[Category: Peterson, B.]]
+
[[Category: Futerman AH]]
-
[[Category: Robinson, G S.]]
+
[[Category: Peterson B]]
-
[[Category: Salinas, P.]]
+
[[Category: Robinson GS]]
-
[[Category: Savickas, P J.]]
+
[[Category: Salinas P]]
-
[[Category: Silman, I.]]
+
[[Category: Savickas PJ]]
-
[[Category: Sussman, J L.]]
+
[[Category: Silman I]]
-
[[Category: Acid-beta-glucosidase]]
+
[[Category: Sussman JL]]
-
[[Category: Alternative initiation]]
+
-
[[Category: Disease mutation]]
+
-
[[Category: Disulfide bond]]
+
-
[[Category: Gaucher disease]]
+
-
[[Category: Glycoprotein]]
+
-
[[Category: Glycosidase]]
+
-
[[Category: Hydrolase]]
+
-
[[Category: Ichthyosis]]
+
-
[[Category: Lipid metabolism]]
+
-
[[Category: Lysosome]]
+
-
[[Category: Membrane]]
+
-
[[Category: N-nonyl-deoxynojirimycin]]
+
-
[[Category: N-nonyl-deoxynojirimycin alternative initiation]]
+
-
[[Category: Sphingolipid metabolism]]
+
-
[[Category: Velaglucerase alfa]]
+

Current revision

Velaglucerase alfa

PDB ID 2wkl

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools